Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110026 | 1.00 | CYP1A2 (0.52) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL22882733 | 0.95 | CYP1A2 (0.53) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL24074957 | 0.93 | LCK (0.55) | CYP1A2CYP1A1CYP19A1LCKKDM4E | |
| SCHEMBL14686061 | 0.90 | CYP1A1 (0.48) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL3671019 | 0.90 | LMNA (0.50) | CYP1A2CYP1A1CYP19A1LCKKDM4E | |
| SCHEMBL14686059 | 0.90 | CYP1A1 (0.48) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL14685934 | 0.90 | CYP1A1 (0.48) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL14685936 | 0.90 | CYP1A1 (0.48) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL24075730 | 0.87 | MAPT (0.42) | CYP1A2CYP1A1CYP19A1LCKSLC5A1 | |
| SCHEMBL26621003 | 0.87 | MAPT (0.45) | CYP1A2CYP1A1CYP19A1LCKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11795127-B2 | Processes for the preparation of ortho-allylated hydroxy aryl compounds | MCMASTER UNIVERSITY (CA) | 2023-10-24 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230113567-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-20210380513-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2021-12-09 | — | — | US | disclosed |
| US-20160068503-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-03-10 | — | — | US | disclosed |
| US-9169230-B2 | (−)-Epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2015-10-27 | — | — | US | disclosed |
| US-20140213802-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2014-07-31 | — | — | US | disclosed |
| US-8710248-B2 | (−)-epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2014-04-29 | — | — | US | disclosed |
| US-20120232135-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2012-09-13 | — | — | US | disclosed |
| US-8193377-B2 | (−)-epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2012-06-05 | — | — | US | disclosed |
| US-20080176931-A1 | e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113567-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | ADH1A, ADH1C, AHR | CYP1A2 45/4885CYP1A1 29/4885CYP19A1 77/4885 |
| US-20120232135-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | PSMC1, PSME1, PSMB1 | CYP1A2 3956/4885CYP1A1 2623/4885CYP19A1 1643/4885 |
| US-20210380513-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | ADH1A, ADH1C, AHR | CYP1A2 45/4885CYP1A1 29/4885CYP19A1 77/4885 |
| US-11795127-B2 | Processes for the preparation of ortho-allylated hydroxy aryl compounds | ADH1A, ADH1C, AHR | CYP1A2 45/4885CYP1A1 29/4885CYP19A1 77/4885 |
| US-20160068503-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | PSMC1, PSME1, PSMB1 | CYP1A2 3956/4885CYP1A1 2623/4885CYP19A1 1643/4885 |
| US-20140213802-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | PSMC1, PSME1, PSMB1 | CYP1A2 3956/4885CYP1A1 2623/4885CYP19A1 1643/4885 |
| US-20080176931-A1 | e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | UBE2G2, C9, BAP1 | CYP1A2 1599/4885CYP1A1 332/4885CYP19A1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.